论文部分内容阅读
化疗是治疗肿瘤的有效手段之一,但肿瘤细胞对化疗药物产生的获得性耐药是抗肿瘤药物应用中的一个重要限制性因素.氨甲喋吟(MTX)是常用的抗肿瘤化疗药之一.但是,肿瘤细胞对MTX容易产生耐药性,且发展较快,出现耐药的同时常伴有二氢叶酸还原酶的活力增高.为了深入研究其耐药机制,有必要建立合适的耐药模型.本文将人的DHFR的突变体(第31位的苯丙氨酸突变为丝氨酸)基因以逆转录病毒为载体分别导入人的乳癌细胞株MDA-231和人红白血病细胞株K562、Raji细胞,建立了几株耐MTX细胞系,研究了其耐药特性和外源基因在细胞中的整合与表达情况.
Chemotherapy is one of the effective methods to treat tumors, but acquired resistance to chemotherapy drugs is an important limiting factor in the application of antitumor drugs. MTX is a commonly used antitumor chemotherapy drug. 1. However, tumor cells are resistant to MTX, and develop rapidly. The emergence of drug resistance is accompanied by increased activity of dihydrofolate reductase. In order to further study its drug resistance mechanism, it is necessary to establish a suitable resistance. Drug model. The human DHFR mutant (mutant phenylalanine to serine at position 31) gene was introduced into the human breast cancer cell line MDA-231 and human erythroleukemia cell line K562, Raji, respectively, using the retrovirus as a vector. The cells were established with several strains of MTX-resistant cells, and their resistance characteristics and the integration and expression of exogenous genes in cells were studied.